| Print
Orexo AB (ORX)
1This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP
Company profile
Orexo AB is a Swedish pharmaceutical company dedicated to advancing treatments for severe diseases and life-saving rescue medications to meet future healthcare needs, developing improved medications based on proprietary drug delivery technologies. At the core of its innovation is AmorphOX, which improves bioavailability and stability for both large and small molecules. It has developed four drugs from concept to approval, including Zubsolv, Abstral, Edluar, and Diabact UBT. The company's current development efforts focus on AmorphOX, with projects in preclinical and clinical phases across multiple therapeutic areas. It operates through US Commercial and HQ & Pipeline, which generate maximum revenue, and operates in the US, EU, and UK generating maximum revenue, and the Rest of the World.
Address
P.O. Box 303 Virdings alle 32 A
Uppsala
SWE
751 05
Telephone
+46 187808800
Forecast key dates
| Name | Key Date |
|---|---|
| Orexo AB Annual General Meeting for 2027 | 2027-05-07T16:00:00 |
| Orexo AB First Quarter Earnings Conference Call for 2027 | 2027-04-28T14:00:00 |
| Orexo AB First Quarter Earnings Results for 2027 | 2027-04-28T00:00:00 |
| Orexo AB Annual Report for 2026 | 2027-03-26T00:00:00 |
| Orexo AB Fourth Quarter Earnings Results for 2026 | 2027-02-04T07:00:00 |
| Orexo AB Fourth Quarter Earnings Conference Call for 2026 | 2027-02-04T00:00:00 |
| Orexo AB Third Quarter Earnings Results for 2026 | 2026-10-22T07:00:00 |
| Orexo AB Third Quarter Earnings Conference Call for 2026 | 2026-10-22T00:00:00 |
| Orexo AB Second Quarter Earnings Results for 2026 | 2026-07-16T07:00:00 |
| Orexo AB Second Quarter Earnings Conference Call for 2026 | 2026-07-16T00:00:00 |
| Orexo AB Annual General Meeting for 2026 | 2026-05-07T16:00:00 |
Previous key dates
| Name | Key Date |
|---|---|
| Orexo AB Annual General Meeting for 2026 | 2026-05-07T16:00:00 |
| Orexo AB First Quarter Earnings Conference Call for 2026 | 2026-04-28T14:00:00 |
| Orexo AB First Quarter Earnings Results for 2026 | 2026-04-28T00:00:00 |
| Orexo AB Annual Report for 2025 | 2026-03-27T00:00:00 |
| Orexo AB Fourth Quarter Earnings Conference Call for 2025 | 2026-02-05T14:00:00 |
| Orexo AB Fourth Quarter Earnings Results for 2025 | 2026-02-05T07:00:00 |
| Orexo AB Third Quarter Earnings Conference Call for 2025 | 2025-10-23T14:00:00 |
| Orexo AB Third Quarter Earnings Results for 2025 | 2025-10-23T08:00:00 |
| Orexo AB Second Quarter Earnings Conference Call for 2025 | 2025-07-16T14:00:00 |
| Orexo AB Second Quarter Earnings Results for 2025 | 2025-07-16T08:00:00 |
| Orexo AB Annual General Meeting for 2025 | 2025-05-08T16:00:00 |
| Orexo AB First Quarter Earnings Conference Call for 2025 | 2025-05-06T14:00:00 |
| Orexo AB First Quarter Earnings Result for 2025 | 2025-05-06T00:00:00 |
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2026 AJ Bell. All rights reserved.